Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.
1. A method for the treatment of asthma in a patient in need thereof, comprising administration of an effective amount of an inhibitor of G βγ signaling, said administration being effective to reduce bronchoconstriction in said patient, wherein said inhibitor of G βγ signaling is a membrane permeable G βγ blocking peptide comprising SEQ ID NO: 1.
2. The method of claim 1 , wherein asthma in said patient is exacerbated by long term use of β2-adrenergic receptor agonists.
3. The method of claim 1 wherein said inhibitor of G βγ signaling is delivered to a patient by a method selected from the group consisting of systemic, oral, intravenous, intramuscular, subcutaneous, intraorbital, intranasal, intracapsular, intraperitoneal, intracisternal, intratracheal, intraarticular administration, and absorption through the skin.
4. The method of claim 1 , wherein said inhibitor of G βγ signaling is formulated for aerosol delivery and is delivered via inhalation.
5. The method of claim 4 , wherein said aerosolized formulation comprises a propellant selected from the group consisting of halocarbons, hydrocarbons and esters.
6. The method of claim 1 , further comprising administration of at least one anti-inflammatory agent selected from the group consisting of corticosteroids, sodium cromolyn, IgE inhibitors, phosphodiesterase inhibitors, methylxanthines, beta-adrenergic agents, and leukotriene modifiers.
7. The method of claim 6 , wherein said anti-inflammatory agent is delivered simultaneously with said inhibitor of G βγ signaling.
8. The method of claim 6 , wherein said anti-inflammatory agent is delivered sequentially, before or after delivery of said inhibitor of G βγ signaling.